自体干细胞移植治疗初治转化性惰性B细胞淋巴瘤首次缓解:国际多中心倾向评分匹配研究
High-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) are used as consolidation in first remission (CR1) in some centres for untreated, transformed indolent B-cell lymphoma (Tr-iNHL) but the evidence base is weak.…
要点
- CR1期ASCT可改善初治转化性惰性B细胞淋巴瘤的无进展生存。
- ASCT组总生存有劣于非ASCT组的趋势,疾病进展死亡比例更高(8% vs 4%)。
- 非ASCT组复发后仍可通过ASCT、CAR-T或异基因移植获得持续CR。
核心结论
- 在初治转化性惰性B细胞淋巴瘤中,CR1期HDC/ASCT改善无进展生存,但对总生存的影响不明确。
研究设计与样本
- 国际多中心回顾性研究,纳入319例符合预设移植条件的初治转化性惰性B细胞淋巴瘤患者。
关键数值与推荐
- 移植 Eligibility 标准:年龄<75岁、LVEF≥45%、无严重肺病、至少标准R-CHOP强度前线化疗后≥3个月PET或CT确认CR。
- 排除非弥漫大B细胞淋巴瘤转化;283例(89%)为滤泡性淋巴瘤,30例(9%)边缘区淋巴瘤,6例(2%)其他亚型。
临床怎么用
- CR1期ASCT可作为改善疾病控制的巩固选项,但需权衡总生存的不确定影响。
- 复发后有效挽救治疗(包括ASCT、CAR-T和异基因移植)仍可获得持续CR,支持个体化决策。
局限性
- 非ASCT组复发后治疗异质,可能影响生存比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) are used as consolidation in first remission (CR1) in some centres for untreated, transformed indolent B-cell lymphoma (Tr-iNHL) but the evidence base is weak. A total of 319 patients with untreated Tr-iNHL meeting prespecified transplant eligibility criteria [age <75, LVEF ≥45%, no severe lung disease, CR by positron emission tomography or computed tomography ≥3 months after at least standard cyclophosphamide, doxorubicin, vincristine and prednisolone with rituximab (R-CHOP) intensity front-line chemotherapy] were retrospectively identified. Non-diffuse large B-cell lymphoma transformations were excluded. About 283 (89%) patients had follicular lymphoma, 30 (9%) marginal-zone lymphoma and six (2%) other subtypes. Forty-nine patients underwent HDC/ASCT in CR1, and a 1:2 propensity-score-matched cohort of 98 patients based on age, stage and high-grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements (HGBL-DH) was generated. After a median follow-up of 3·7 (range 0·1-18·3) years, ASCT was associated with significantly superior progression-free survival [hazard ratio (HR) 0·51, 0·27-0·98; P = 0·043] with a trend towards inferior overall survival (OS; HR 2·36;0·87-6·42; P = 0·1) due to more deaths from progressive disease (8% vs. 4%). Forty (41%) patients experienced relapse in the non-ASCT cohort - 15 underwent HDC/ASCT with seven (47%) ongoing complete remission (CR); 10 chimeric antigen receptor-modified T-cell (CAR-T) therapy with 6 (60%) ongoing CR; 3 allogeneic SCT with 2 (67%) ongoing CR. Although ASCT in CR1 improves initial duration of disease control in untreated Tr-iNHL, the impact on OS is less clear with effective salvage therapies in this era of CAR-T.
引用
- Chin CK, Lim KJ, Lewis K, et al. Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study. Br J Haematol. 2020. PMID: 33065767. doi:10.1111/bjh.17072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。